

Other version: http://www.intmedpress.com/journals/avt/abstract.cfm?id=690&pid=88
![]() |
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients |
|
Authors | ![]() | |
Published in | Antiviral therapy. 2005, vol. 10, no. 6, p. 761-767 | |
Abstract | OBJECTIVE: To assess the efficacy and safety of first-line treatment with once-daily saquinavir/ritonavir with two nucleoside reverse transcriptase inhibitors (NRTIs), as induction therapy before enrollment in a randomized trial of structured treatment interruption strategies. DESIGN: Two-hundred antiretroviral-naive patients with CD4+ cell counts between 200-350 at screening were enrolled in this open-label 24week study. METHODS: Patients were followed up every 8 weeks for CD4+ cells, HIV RNA, and clinical and laboratory toxicities. RESULTS: Two-hundred patients were enrolled with median baseline CD4+ cell count of 267 cells/microl and HIV RNA 50 118 (4.7 log10) copies/mi. After 24 weeks of treatment, 191 of 200 (96%) patients had below 400 copies/ml HIV RNA, with 177/200 (89%) below 50 copies/ml (intent to treat, missing equals failure method), with a median rise in CD4+ cell count of 122 cells/microl. There was no significant correlation between the minimum concentration of saquinavir and HIV RNA reductions at week 8 (P = 0.957) or absolute HIV RNA at week 24 (P = 0.77). CONCLUSION: First-line highly active antiretroviral therapy (HAART) with once-daily saquinavir/ritonavir plus two NRTIs showed strong antiviral efficacy over 24 weeks, and should be evaluated in larger prospective randomized clinical trials. | |
Keywords | Adult — Anti-HIV Agents/administration & dosage/adverse effects/therapeutic use — Antiretroviral Therapy, Highly Active/ adverse effects — CD4 Lymphocyte Count — Drug Therapy, Combination — Female — HIV Infections/ drug therapy/virology — HIV-1/drug effects — Humans — Male — Prospective Studies — RNA, Viral/blood — Reverse Transcriptase Inhibitors/administration & dosage/adverse — Effects/ therapeutic use — Ritonavir/administration & dosage/adverse effects/therapeutic use — Saquinavir/administration & dosage/adverse effects/therapeutic use — Thailand — Treatment Outcome | |
Identifiers | PMID: 16218176 | |
Full text |
![]() ![]() Other version: http://www.intmedpress.com/journals/avt/abstract.cfm?id=690&pid=88 |
|
Structures | ||
Citation (ISO format) | ANANWORANICH, Jintanat et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients. In: Antiviral therapy, 2005, vol. 10, n° 6, p. 761-767. https://archive-ouverte.unige.ch/unige:7079 |